About Us
About Guard Therapeutics
Vision, Business Model & Goal
The Board
Management
Research
Kidney disease
Science
Pipeline
RMC-035
GTX Peptides
Investor Relations
Financial calender
Financial reports
Share information
Corporate governance
General meetings
Newsroom
Press releases
Event calender
Analyses and presentations
Subscribe
Contact
Swe
Search
Novel Therapies Targeting Kidney Disease
Latest Press Releases
Guard Therapeutics intends to resolve on a rights issue of approximately SEK 150 million
(regulatory)
Read more
Guard Therapeutics establishes scientific advisory committee to support Phase 3 development of RMC-035
Read more
25% of patients recruited in Guard Therapeutics phase 2b POINTER study
Read more
Press releases
17 Feb 2025 · Regulatory information
Guard Therapeutics intends to resolve on a rights issue of approximately SEK 150 million
Read more
22 Jan 2025
Guard Therapeutics establishes scientific advisory committee to support Phase 3 development of RMC-035
Read more
08 Jan 2025
25% of patients recruited in Guard Therapeutics phase 2b POINTER study
Read more
04 Dec 2024 · Regulatory information
Guard Therapeutics presents the Nomination Committee for 2025
Read more
Show more
In focus
17 Oct 2024 / Presentation
Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"
Read more
23 Sep 2024 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read more
19 Sep 2024 / Presentation
Presentation at Pareto Securities' 15th Annual Healthcare Conference
Read more
30 Jan 2024 / Presentation
Guard Therapeutics R&D update January 30, 2024
Read more
Show more
Upcoming events
13 Mar 2025
Guard presents at Carnegie Healthcare Day 13 March
04 Apr 2025
Michael Reusch, faculty member at the Kidney Disease Clinical Trialists Workshop April 4-5
Read more
14 Apr 2025
Annual Report 2024 (approximate date)
Read more
05 May 2025
Interim report January-March 2025
Read more
Show more
Event calendar
/
Financial calendar